Menu
← Oncology Approval Tracker
FDA DECISION ·
Kisqali + fulvestrant
ribociclib with fulvestrant · Novartis
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with HR-positive, HER2-negative advanced or metastatic breast cancer; ribociclib with fulvestrant as initial endocrine-based therapy or after progression on endocrine therapy.
LAMPGEN ANALYSIS
Why it matters
This supplement broadened the fulvestrant combination from its earlier postmenopausal population to the labeled adult population.
What research teams should watch
Record menopausal status and the need for concurrent gonadal suppression; retain the endocrine history and ECG and blood test schedule.
PRIMARY RECORDS